Title:
NOVEL SPIRO COMPOUND
Document Type and Number:
WIPO Patent Application WO/2023/074847
Kind Code:
A1
Abstract:
The present invention provides: a novel spiro compound having a TRH-DE inhibition activity and useful for the prevention/treatment of various diseases associated with TRH and/or symptoms associated with the diseases, or a pharmacologically acceptable salt thereof; a method for producing the compound or a pharmacologically acceptable salt thereof; a use of the compound or a pharmacologically acceptable salt thereof; a pharmaceutical composition which contains the compound or a pharmacologically acceptable salt thereof as an active ingredient; and others. The present invention is a compound represented by general formula [I]: [wherein the ring A represents an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted aliphatic heterocyclic ring group; and R1 and R2 independently represent an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkenyl group, an optionally substituted cycloalkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aliphatic heterocyclic ring group which may contain a double bond in a portion of the ring, an optionally substituted amino group, an optionally substituted alkoxy group, or an optionally substituted alkylthio group, or R1 and R2 together form a ring] or a pharmacologically acceptable salt thereof.
Inventors:
HAYASHI NORIMITSU (JP)
IKUBO MASAYA (JP)
NAKAO AKIRA (JP)
OGATA SHINGO (JP)
NAGAOKA MINAMI (JP)
FUKUNAGA KENJI (JP)
KANNO RENTAROU (JP)
YAMADA TAKAHIRO (JP)
IKUBO MASAYA (JP)
NAKAO AKIRA (JP)
OGATA SHINGO (JP)
NAGAOKA MINAMI (JP)
FUKUNAGA KENJI (JP)
KANNO RENTAROU (JP)
YAMADA TAKAHIRO (JP)
Application Number:
PCT/JP2022/040370
Publication Date:
May 04, 2023
Filing Date:
October 28, 2022
Export Citation:
Assignee:
MITSUBISHI TANABE PHARMA CORP (JP)
International Classes:
C07D205/12; A61K31/397; A61K31/4025; A61K31/4035; A61K31/416; A61K31/4178; A61K31/4184; A61K31/429; A61K31/437; A61K31/4375; A61K31/4427; A61K31/4436; A61K31/4725; A61K31/4985; A61K31/502; A61K31/506; A61K31/5355; A61K31/5377; A61K31/541; A61K31/55; A61K31/551; A61K31/553; A61K31/554; A61P25/04; A61P25/16; A61P25/20; A61P25/24; A61P25/28; A61P43/00; C07D401/04; C07D401/12; C07D401/14; C07D403/04; C07D403/12; C07D403/14; C07D405/14; C07D409/14; C07D413/04; C07D413/14; C07D417/04; C07D471/04; C07D487/04; C07D498/04; C07D513/04; C07D519/00
Domestic Patent References:
| WO2022046861A1 | 2022-03-03 | |||
| WO2022140472A1 | 2022-06-30 | |||
| WO2022224166A1 | 2022-10-27 | |||
| WO2021204159A1 | 2021-10-14 | |||
| WO2001060843A1 | 2001-08-23 | |||
| WO2006038206A2 | 2006-04-13 | |||
| WO2007113784A2 | 2007-10-11 |
Other References:
CHARLI JEAN-LOUIS, RODRÍGUEZ-RODRÍGUEZ ADAIR, HERNÁNDEZ-ORTEGA KARINA, COTE-VÉLEZ ANTONIETA, URIBE ROSA MARÍA, JAIMES-HOY LORRAINE: "The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?", FRONTIERS IN PHARMACOLOGY, vol. 11, 8 May 2020 (2020-05-08), pages 640, XP093060600, DOI: 10.3389/fphar.2020.00640
Attorney, Agent or Firm:
TSUKUNI & ASSOCIATES et al. (JP)
Download PDF:
Previous Patent: LITHIUM SECONDARY BATTERY
Next Patent: FINE CELLULOSE FIBER POWDER AND METHOD FOR PRODUCING FINE CELLULOSE FIBER POWDER
Next Patent: FINE CELLULOSE FIBER POWDER AND METHOD FOR PRODUCING FINE CELLULOSE FIBER POWDER